DanaherDHR

NYSE · USA · Segment 5 of 8 in the Medicine, pharma & life science value chain: Life science tools

Cytiva supplies the equipment biologics are made with; Cepheid runs molecular diagnostics. Danaher owns both, along with a wider set of life science instruments.

Life science tools: Instruments, reagents and equipment for research, development and production.

Key metrics

Market cap

$144B

Price

$215.11

Today

−1.7%

Return YTD

−4.4%

Return 1Y

+7.3%

P/E

35.9

P/S

5.7

P/B

2.7

Data as of 2026-08-25 · updates daily after U.S. close

Theme exposure

Life science toolsBioprocessingDiagnostics exposureDiagnostics

In the value chain

Products & services

Bioprocessing (Cytiva)
Molecular diagnostics (Cepheid)
Life science instruments

Competitors

Thermo Fisher
Sartorius
Agilent

Risks

Cyclical bioprocessing demand
Customer inventory normalisation

Supply chain

Supplies →

RegeneronREGN AmgenAMGN Eli LillyLLY

Full supply chain for DHR →

Same segment: Life science tools

Thermo Fisher ScientificTMO Agilent TechnologiesA Waters CorporationWAT IlluminaILMN RevvityRVTY

Compare DHR

DHR vs TMO DHR vs A DHR vs WAT DHR vs ILMN DHR vs RVTY

See where Danaher sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →